Abstract:Background. A large number of cancer-related deaths in the world can be attributed to liver hepatocellular carcinoma (LIHC). The purpose of this study is to explore protein tyrosine phosphatase type IV A member 3 (PTP4A3/PRL-3) as a new and reliable biomarker to predict the prognosis of LIHC and determine the potential therapeutic targets or drugs that can be used for treating LIHC. Methods. We included three LIHC datasets with clinical information and expression profiles from public databases. The expression level of PTP4A3 was analyzed, and based on the results, the samples were divided into high- and low-expression groups. The Kaplan–Meier survival analysis method was used to determine the relationship between PTP4A3 and prognosis. The enrichment differences among the functional pathways associated with the high- and low-expression groups were determined using the gene set enrichment analysis (GSEA) method. Five methods were used to determine the differences among the tumor microenvironment in the low- and high-expression groups. The sensitivity of the low- and high-expression groups toward different drug treatment methods was predicted by analyzing the Tumor Immune Dysfunction and Exclusion (TIDE) scores and determining the biochemical half-maximal inhibitory concentration (IC50). Results. The expression levels of the LIHC and adjacent samples were analyzed, and it was observed that the expression level of PTP4A3 in tumor tissue was significantly higher than the expression level of the same gene in the adjacent samples. It was also inferred that it might be a cancer-promoting gene. It was concluded that high-expression results in a significantly poor prognosis. The high-expression group was significantly enriched in the tumor-related pathways, such as the PI3K-AKT signaling pathway. In addition, the results obtained by conducting immune infiltration analysis revealed a significant positive correlation between some immune scores and the gene PTP4A3. The drug KIN001−135 and gene PTP4A3 were also found to correlate positively with each other. CP466722, Pyrimethamine, AKT inhibitor VIII, Embelin, Cisplatin, QS11, Bexarotene, and Midostaurin negatively correlated with PTP4A3 associated with the three datasets. Moreover, the drugs Cisplatin, QS11, Midostaurin, and CP466722 were more sensitive toward the high-expression group than the low PTP4A3 expression group. Significant differences were observed in these cases. Conclusion. PTP4A3/PRL-3 is potentially associated with the progression, metastasis, and invasion of LIHC. The prognosis of LIHC patients is negatively impacted by the high-expression levels of the gene. The results indicate that PTP4A3/PRL-3 is an important prognostic factor for LIHC and is a new potential prognostic detection target. The discovery of the 8 drugs that were negatively associated with PTP4A3 provided a new direction that can be developed in the future for the treatment of LIHC.

PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma

CLIC1 Drives Angiogenesis in Hepatocellular Carcinoma by Modulating VEGFA

Integrated Bioinformatics Analysis Reveals the Function and Prognostic Value of OSBPL3 in Hepatocellular Carcinoma

Phosphatase Regenerating Liver 3 Participates in Integrinβ1/FAK-Src/MAPK Signaling Pathway and Contributes to the Regulation of Malignant Behaviors in Hepatocellular Carcinoma Cells

Protocadherin-1 Serves As a Prognostic Biomarker and Promotes Pancreatic Cancer Progression by Suppressing CD8+ T Cell Infiltration Through CCL5-CCR5 Axis.

Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma

CDCA3 is a Novel Prognostic Biomarker Associated with Immune Infiltration in Hepatocellular Carcinoma

Supplemental Information from hPCL3s Promotes Hepatocellular Carcinoma Metastasis by Activating β-Catenin Signaling

Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

Hpcl3s Promotes Hepatocellular Carcinoma Metastasis by Activating Β-Catenin Signaling.

Identification of PLOD Family Genes as Novel Prognostic Biomarkers for Hepatocellular Carcinoma

A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 signaling pathway in HCC

Screening of PDSS1 as a Potential Biomarker for Hepatocellular Carcinoma Based on a Copper-Related Prognostic Signature through Bulk and Single-cell RNA-sequencing Analysis

Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma.

Single-cell analysis identified PDIA3 as regulator of malignant characteristics and macrophage function in human cancers

Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma

Prognostic Value of PRL-3 Overexpression in Early Stages of Colonic Cancer.

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors

Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis

Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma

Clinical Significance of PD-1/PD-Ls Gene Amplification and Overexpression in Patients with Hepatocellular Carcinoma.